Table 5.
HADS Depression and Anxiety change from pre-medication baseline, for both the total sample and for abstainers only, at EOT (8-weeks post-TQD) for STRATUS EU & US (STRATUS META did not administer the HADS). None of the comparisons were significant compared to placebo. Values are presented as least square means (standard error).
| Study | Placebo | 5 mg | 20 mg | |||
|---|---|---|---|---|---|---|
| HADS Anxiety | ||||||
| STRATUS EU | −0.82 | (0.23) | −0.59 | (0.23) | −0.24 | (0.22) |
| Abstainers only | −1.15 | (0.41) | −0.92 | (0.36) | −0.70 | (0.35) |
| STRATUS US | −0.56 | (0.21) | −0.89 | (0.21) | −0.52 | (0.20) |
| Abstainers only | −1.07 | (0.44) | −1.29 | (0.45) | −0.86 | (0.35) |
| POOLED EU/US | −0.68 | (0.15) | −0.75 | (0.15) | −0.38 | (0.15) |
| Abstainers only | −1.11 | (0.30) | −1.06 | (0.28) | −0.80 | (0.25) |
| HADS Depression | ||||||
| STRATUS EU | −0.31 | (0.20) | −0.18 | (0.20) | 0.19 | (0.19) |
| Abstainers only | −0.42 | (0.36) | −0.05 | (0.32) | −0.08 | (0.31) |
| STRATUS US | −0.45 | (0.18) | −0.89 | (0.19) | −0.32 | (0.17) |
| Abstainers only | −1.15 | (0.37) | −0.82 | (0.37) | −0.59 | (0.29) |
| POOLED EU/US | −0.35 | (0.13) | −0.53 | (0.13) | −0.06 | (0.13) |
|
| ||||||
| Abstainers only | −0.76 | (0.26) | −0.35 | (0.24) | −0.34) | (0.22) |
Note: HADS = The Hospital Anxiety and Depression Scale. EOT = end of treatment; TQD = targeted quit date.